{
  "author": "Omg_Keynes",
  "the_new_excerpt": " * Eli Lilly (NYSE:LLY\n   [https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link])\n   gains 20% in premarket on promising results\n   [https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of…",
  "original_created_utc": 1610373330,
  "localize": [
    {
      "locale": "zh",
      "the_new_excerpt": " * Eli Lilly (NYSE:LLY\n   [https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link])\n   gewinnt 20% im vorbörslichen Handel aufgrund vielversprechender Ergebnisse\n   [https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of...",
      "title": "Eli Lilly legt um 20% zu, nachdem Donanemab klinischen Nutzen in Alzheimer-Studie im mittleren Stadium zeigt"
    },
    {
      "locale": "zh-Hant",
      "the_new_excerpt": " * Eli Lilly (NYSE:LLY\n   [https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link])\n   gewinnt 20% im vorbörslichen Handel aufgrund vielversprechender Ergebnisse\n   [https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of...",
      "title": "Eli Lilly legt um 20% zu, nachdem Donanemab klinischen Nutzen in Alzheimer-Studie im mittleren Stadium zeigt"
    }
  ],
  "title": "Eli Lilly up 20% after donanemab shows clinical benefit in mid-stage Alzheimer's study",
  "created_utc": 1610496697,
  "selftext_html": "<!-- SC_OFF --><div class=\"md\"><ul>\n<li>Eli Lilly (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">LLY</a>) gains 20% in premarket on <a href=\"https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of-alzheimers-disease-in-positive-phase-2-trial?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">promising results</a> from <a href=\"https://clinicaltrials.gov/ct2/show/NCT03367403?cond=trailblazer&amp;draw=2&amp;rank=1&amp;source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">Phase 2 TRAILBLAZER-ALZ study</a>, evaluating donanemab, an antibody that targets a  modified form of beta amyloid called N3pG, for Alzheimer&#39;s disease  (AD). The study met the primary endpoint of change from baseline to 76  weeks in AD rating scale.</li>\n<li>Data  showed that donanemab slowed the decline in a composite measure of  cognition and daily function by 32%, compared to placebo.</li>\n<li>Safety profile was consistent with observations from Phase 1 data.</li>\n<li>Full  results of the TRAILBLAZER-ALZ study will be presented at a future  medical congress and submitted for publication in a peer-reviewed  clinical journal.</li>\n<li>Lilly plans to  discuss these results with regulators to assess next steps for  donanemab. In addition, TRAILBLAZER-EXT is an ongoing trial for those  who participated in TRAILBLAZER-ALZ.</li>\n<li>Safety, tolerability and efficacy of donanemab are also being evaluated in another <a href=\"https://clinicaltrials.gov/ct2/show/NCT04437511?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">Phase 2 study TRAILBLAZER-ALZ 2</a>.</li>\n<li>Progress on Alzheimer&#39;s treatments was one reason cited by BofA in picking Lilly as a <a href=\"https://seekingalpha.com/news/3649105-bofas-biopharma-picks-2021-set-to-build-new-launches-beatable-expectations?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">top name for 2021</a>.</li>\n</ul>\n\n<p><a href=\"https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-clinical-benefit-in-mid-stage-alzheimers-study\">https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-clinical-benefit-in-mid-stage-alzheimers-study</a></p>\n</div><!-- SC_ON -->",
  "score": 35,
  "permalink": "/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/",
  "subreddit": "investing",
  "id": "kv332t",
  "is_self": true,
  "media": null,
  "is_video": false,
  "source_updated_at": 1610706379515
}